Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy

Table 3 Factors affecting the new tumor formation within one year in 22 patients after RFA.

	New tumor(n = 8)	No new tumor(n = 14)	P
Age (yr)	55.1±8.3	66.7±10.8	0.029
Sex (male/female)	6/2	10/4	NS6
Child1 (A/B)	5/3	13/1	0.076
Right lobe/Left lobe	5/3	11/3	NS
Subcapsular (+/-)	2/6	2/12	NS
HBV/HCV/others	3/4/1	6/6/2	NS
EV2 (+/-)	2/6	9/5	0.076
Tumor size (cm)	2.4±0.8	2.2±0.8	NS
Tumor >2 cm (+/-)	5/3	7/7	NS
Histology
(Well/Poor)3	7/1	14/0	NS
BCLC stage4 Ia/Ib/Ic	2/5/1	9/5/0	NS
Roll-off (+/-)	8/0	13/1	NS
Ablative time (min)	20.8±10.8	21.6±15.5	NS
Sessions	1.1±0.4	1.2±0.4	NS
Follow-up (mo)	26.8±10.4	30.0±8.3	NS
Pre-RFA/Post-RFA
Albumin (g/dL)	3.6±0.5/4.1±0.7	4.0±0.4/4.2±0.5	0.059/NS
T.Bili (mg/dL)	1.3±0.6/1.0±0.3	1.0±0.4/1.1±0.6	NS/NS
GOT (U/L)	54.3±18.1/61.0±23.1	68.7±38.5 /75.8±38.9	NS/NS
GPT (U/L)	63.336.5/82.141.1	75.6±42.5/77.6±31.1	NS/NS
Alk-P (U/L)	117.0±33.3/126.9±45.1	115.5±53.5/121.6±48.2	NS/NS
AFP5 (ng/mL)	388.5±1 003.2/77.9±142.4	129.2±376.8/20.4±32.4	NS/NS
Decrease AFP > 50%	4/4	4/10	NS
Post-RFA(+/-)

¹Child: Child-Pugh classification.

²EV: esophageal varices

³Well/Poor: Well differentiated/Poor differentiated

⁴BCLC stage: staging system from conclusions of the Barcelona-2000 EASL conference[16]

⁵AFP: alpha-fetoprotein

⁶NS: not significant.